Halogenated Benzodiazepine TSPO Activators for Neuroinflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments are inadequate for reducing methamphetamine cravings and addressing the medical and behavioral consequences of methamphetamine use, as well as HIV-associated cognitive and neurodegenerative disorders, due to limitations in penetrating the blood-brain barrier and targeting neuroinflammatory responses.
Innovation Solution
Pharmacological activation of the translocator protein of 18 kDa (TSPO) using benzodiazepines with a halogen moiety, such as Ro5-4864, to treat chronic methamphetamine addiction, HIV-associated cognitive motor disorders, and neuroinflammatory responses, while minimizing binding to the GABAA receptor.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for methamphetamine addiction, then they fail to penetrate the blood-brain barrier effectively, but this limitation prevents them from targeting neuroinflammatory responses and reducing cravings
Solution Approach 1:
The patent modifies the chemical structure of benzodiazepine compounds by introducing a halogen moiety at the 4' position, which changes the pharmacokinetic parameters of the drug to enable effective penetration of the blood-brain barrier while maintaining affinity for TSPO receptors in the brain
Solution Approach 2:
The patent uses TSPO (translocator protein of 18 kDa) as a molecular intermediary target in the brain. The modified benzodiazepine compounds bind to TSPO, which is expressed on microglial cells and other brain cells, thereby mediating the therapeutic effect of reducing neuroinflammation and methamphetamine cravings
2Reliability
If benzodiazepines with high GABAA receptor binding are used, then they produce sedative effects, but this causes unwanted side effects that reduce treatment compliance
Solution Approach 1:
The patent creates compounds with selective binding properties: the halogenated benzodiazepines have high affinity for TSPO receptors in the brain (local target) while having reduced affinity for GABAA receptors. This local quality differentiation allows the drug to act specifically on neuroinflammatory pathways without producing systemic sedative effects
Solution Approach 2:
The patent changes the binding affinity parameters of the benzodiazepine compounds by modifying their chemical structure. The halogen substitution at the 4' position specifically alters the interaction profile with TSPO versus GABAA receptors, enhancing selective binding to TSPO while reducing GABAA receptor engagement and associated side effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively reduces methamphetamine cravings, halts methamphetamine-seeking behaviors, reverses cognitive deficits, and decreases the incidence of risky sexual behaviors associated with HIV transmission, by modulating neuroinflammatory responses and enhancing memory functions.
Implementation Method 1
Pharmacological activation of the translocator protein of 18 kDa (TSPO) using benzodiazepines with a halogen moiety, such as Ro5-4864
Data Source
AI summary
A method of treating a condition of in a human patient comprising pharmacologically activating a translocator protein of 18 kDa (TSPO), wherein the condition is one of a chronic methamphetamine addiction, a medical consequence of methamphetamine use; a behavioral consequence of methamphetamine use, an HIV associated cognitive motor disorder, an HIV-associated neurodegenerative disorder, and a neuroinflammatory response.